---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-017235"
form_type: "8-K"
ticker: "GKOS"
cik: "0001192448"
company_name: "GLAUKOS Corp"
filed_at: "2023-11-01T23:59:59+00:00"
generated_at: "2026-06-09T02:03:00.058724+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Glaukos Q3 net sales up 10% to $78M; raises FY2023 guidance to $307-310M

## Summary
- Net sales $78.0M (+10% YoY); glaucoma $58.3M (+9%), corneal health $19.7M (+12%).
- GAAP net loss $30.4M ($0.63/share); non-GAAP net loss $24.2M ($0.50/share).
- Raised FY2023 net sales guidance to $307-310M from $304-308M.
- Cash and equivalents $307M at quarter end.

## SEC filing metadata
- accession: 0001558370-23-017235
- form_type: 8-K
- ticker: GKOS
- cik: 0001192448
- company_name: GLAUKOS Corp
- filed_at: 2023-11-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1192448/000155837023017235/0001558370-23-017235-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1192448/000155837023017235/gkos-20231101x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-017235
- JSON: https://secwatch.observer/filing/0001558370-23-017235.json
- Plain text: https://secwatch.observer/filing/0001558370-23-017235.txt

## Key facts
- Earnings Releases
  GLAUKOS Corp reported third quarter ended September 30, 2023 results: revenue $78.0 million, net income ($30.4 million, or ($0.63) per diluted share). Guidance raised.
  - Period: third quarter ended September 30, 2023
  - Revenue: $78.0 million
  - Net income: ($30.4 million, or ($0.63) per diluted share)
  - Guidance: raised
  - Result: reported results
  source text: of glaucoma, corneal disorders and retinal diseases, today announced financial results for the third quarter ended September 30, 2023. Key highlights include: · Net sales of $78.0 million in Q3 2023 increased 10% year-over-year on a reported basis and 9% year-over-year on a constant currency basis. · Glaucoma net sales of $58.3 million in Q3 2023 increased 9%
  evidence_url: https://www.sec.gov/Archives/edgar/data/1192448/000155837023017235/0001558370-23-017235-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.